Comparative Pharmacology
Head-to-head clinical analysis: IMATINIB MESYLATE versus PEMAZYRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMATINIB MESYLATE versus PEMAZYRE.
IMATINIB MESYLATE vs PEMAZYRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imatinib mesylate is a tyrosine kinase inhibitor that selectively inhibits BCR-ABL, c-KIT, and PDGFR tyrosine kinases, thereby blocking signal transduction pathways involved in cellular proliferation and survival.
Selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4; binds to and inhibits FGFR kinase activity, leading to decreased tumor cell proliferation and angiogenesis.
400 mg orally once daily, with a meal and a large glass of water. Dose escalation to 600 mg or 800 mg daily may be considered in cases of disease progression.
13.5 mg orally once daily continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 18 hours (range 13–22 hours) for the parent drug; the active metabolite N-desmethyl imatinib has a half-life of about 40 hours. Clinically, this supports once-daily dosing.
Terminal elimination half-life is approximately 20 hours (range 14–32 h), supporting once-daily dosing with steady-state reached within 8 days.
Primarily fecal (68% of dose) as metabolites; renal excretion accounts for approximately 13% of dose (5% as unchanged drug and 8% as metabolites).
Primarily hepatobiliary excretion: 72% of the dose recovered in feces (mainly as unchanged drug and metabolites); renal excretion accounts for approximately 17% (less than 1% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor